Comorbidities of idiopathic pulmonary fibrosis

Thematic Poster
Chairs: S. Torrisi (Acireale (CT), Italy), S. Tomassetti (Forli, Italy), T. Alfaro (Coimbra, Portugal), V. Somogyi (Heidelberg, Germany)

Prognosis symptoms, quality of life and comorbidity relationship with cough in patients with idiopathic pulmonary fibrosis S. Kucuk (Kocaeli, Turkey), I. Basyigit (Kocaeli, Turkey), S. Argun Baris (Kocaeli, Turkey), H. Boyaci (Kocaeli, Turkey)
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments M. Nieto Barbero (Madrid, Spain), F. Gonzalez-Gamiz (Madrid, Spain), M. Rodríguez-Nieto (Madrid, Spain), S. Sanchez (Alcaá de Henares, Spain), J. Gaudo (Madrid, Spain), C. Valenzuela (Madrid, Spain), B. López-Muñíz (Madrid, Spain), L. Gomez-Carrera (Madrid, Spain), R. Laporta (Majadahonda, Spain), Á. Casanova (Coslada, Spain), M. Río (Getafe, Spain), R. Neumomadrid (Madrid, Spain)
Effect of gastroesophageal reflux (GER) on the progression of pulmonary fibrosis J. weerawattana (Bangkok, Thailand), T. Patcharatrakul (Bangkok, Thailand), T. Tongbai (Bangkok, Thailand), S. Gonlachanvit (Bangkok, Thailand), K. Kawkitinarong (Bangkok, Thailand)
Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF) P. Mari (Rome, Italy), S. Kay (Ann Arbor, United States of America), E. Belloli (Ann Arbor, United States of America), M. Salisbury (Ann Arbor, United States of America), J. Sheth (Ann Arbor, United States of America), C. Holtze (Ann Arbor, United States of America), B. Wang (Ann Arbor, United States of America), J. Myers (Ann Arbor, United States of America), K. Konopka (Ann Arbor, United States of America), A. Lagstein (Ann Arbor, United States of America), E. Kazerooni (Ann Arbor, United States of America), A. Chughtai (Ann Arbor, United States of America), D. Vummidi (Ann Arbor, United States of America), V. Nagaraja (Ann Arbor, United States of America), D. Khanna (Ann Arbor, United States of America), K. Flaherty (Ann Arbor, United States of America), L. Richeldi (Rome, Italy), E. White (Ann Arbor, United States of America)
Right ventricular systolic pressure as a prognostic factor for pulmonary hypertension with interstitial lung disease T. Kawaguchi (Kitakyusyu, Japan), H. Kitamura (Yokohama, Japan), S. Kato (Yokohama, Japan), R. Ohtoshi (Yokohama, Japan), E. Tabata (Yokohama, Japan), T. Oda (Yokohama, Japan), E. Hagiwara (Yokohama, Japan), K. Fukui (Yokohama, Japan), K. Yatera (Kitakyusyu, Japan), T. Ogura (Yokohama, Japan)
Cognitive impairment in patients with Idiopathic Pulmonary Fibrosis - Obstructive Sleep Apnea Overlap E. Tudorache (Timisoara, Romania), D. Traila (Timisoara, Romania), M. Marc (Timisoara, Romania), O. Fira Mladinescu (Timisoara, Romania), D. Manolescu (Timisoara, Romania), B. Timar (Timisoara, Romania), C. Oancea (Timisoara, Romania)
CD163 positive alveolar macrophages from bronchoalveolar lavage in idiopathic pulmonary fibrosis and lung cancer. E. Bibaki (Heraklion, Greece), E. Vasarmidi (Heraklion, Greece), C. Koutoulaki (Heraklion, Greece), S. Mastrodemou (Heraklion, Greece), A. Trachalaki (Heraklion, Greece), N. Tzanakis (Heraklion, Greece), E. Tsitoura (Heraklion, Greece), K. Antoniou (Heraklion, Greece)
Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival E. Bárczi (Budapest, Hungary), T. Nagy (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohács (Budapest, Hungary), V. Müller (Budapest, Hungary)
Differentiating between depression, anxiety and a grief reaction in idiopathic pulmonary fibrosis (IPF) patients and their caregivers. Is it time to rethink how and what we measure? D. Reynolds-Sandford (Adelaide, Australia), P. Reynolds (Adelaide, Australia), H. Jersmann (Adelaide, Australia), O. Schubert (Adelaide, Australia)
Subtypes of lung adenocarcinomas associated with IPF G. Gomatou (Athens, Greece), R. Tringidou (Athens, Greece), T. Karampitsakos (Athens, Greece), V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), D. Bouros (Athens, Greece)
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study T. Karampitsakos (Athens, Greece), G. Gomatou (Athens, Greece), V. Tzilas (Athens, Greece), E. Bouros (Athens, Greece), E. Markozannes (Athens, Greece), E. Manali (Athens, Greece), I. Tomos (Athens, Greece), K. Antoniou (Heraklion, Greece), A. Trachalaki (Heraklion, Greece), L. Kolilekas (Athens, Greece), I. Korbila (Athens, Greece), P. Tomos (Athens, Greece), S. Chrysikos (Athens, Greece), K. Dimakou (Athens, Greece), K. Loverdos (Athens, Greece), A. Gaga (Athens, Greece), Z. Daniil (Larissa, Greece), F. Bardaka (Larissa, Greece), I. Papanikolaou (Corfu, Greece), D. Papakosta (Thessaloniki, Greece), K. Markopoulou (Thessaloniki, Greece), R. Tringidou (Athens, Greece), S. Papiris (Athens, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Athens, Greece)
Risk of cancer incidence in patient with idiopathic pulmonary fibrosis: An analysis of the National Health Insurance Service database of Korea H. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lee (Seoul, Republic of Korea), K. Han (Seoul, Republic of Korea), S. Choi (Seoul, Republic of Korea)
Predictive value of 18F-FDG PET/CT for chemotherapy-related acute exacerbation of interstitial lung disease in lung cancer patients with interstitial lung disease K. Akaike (Kumamoto, Japan), K. Saruwatari (Kumamoto, Japan), S. Oda (Kumamoto, Japan), S. Hamada (Kumamoto, Japan), Y. Tomita (Kumamoto, Japan), S. Saeki (Kumamoto, Japan), H. Ichiyasu (Kumamoto, Japan), K. Fujii (Kumamoto, Japan), S. Shiraishi (Kumamoto, Japan), T. Sakagami (Kumamoto, Japan)
Central European idiopathic pulmonary fibrosis (IPF) patients survey K. Lewandowska (Warsaw, Poland), I. Beunders (Baden, Austria), M. Sterclova (Prague, Czech Republic), S. Majewski (Lodz, Poland), K. Gorska (Warsaw, Poland), B. Zolnowska (Warsaw, Poland), V. Muller (Budapest, Hungary), T. Peros-Golubicic (Zagreb, Croatia), S. Jimmy (Tel-Aviv, Israel), G. Wanke (Vienna, Austria), M. Vasakova (Prague, Czech Republic), J. Kus (Warsaw, Poland)
The health status in idiopathic pleuroparenchymal fibroelastosis Y. Mori (Seto, Japan), Y. Yamano (Seto, Japan), T. Yokoyama (Seto, Japan), T. Matsuda (Seto, Japan), K. Kataoka (Seto, Japan), T. Kimura (Seto, Japan), Y. Kondoh (Seto, Japan)
Late Breaking Abstract - Calcium-sensing receptor activators increased in the sputum of idiopathic pulmonary fibrosis patients K. Wolffs (Cardiff, United Kingdom), B. Mansfield (Cardiff, United Kingdom), R. Bruce (Cardiff, United Kingdom), L. Verckist (Antwerp, Belgium), R. Paes De Araújo (Ceredigion, United Kingdom), R. Attanoos (Cardiff, United Kingdom), D. Adriaensen (Antwerp, Belgium), L. Mur (Ceredigion, United Kingdom), B. Hope-Gill (Penarth, United Kingdom), D. Riccardi (Cardiff, United Kingdom)
Late Breaking Abstract - Change in airway volume, measured with functional respiratory imaging (FRI), differentiates between stable and progressive idiopathic pulmonary fibrosis (IPF) T. Mclellan (Cambridge, United Kingdom), P. George (London, United Kingdom), P. Ford (Antwerp, Belgium), J. De Backer (Antwerp, Belgium), C. Van Holsbeke (Antwerp, Belgium), B. Mignot (Antwerp, Belgium), A. Ruggiero (Cambridge , United Kingdom), M. Thillai (Cambridge , United Kingdom)